Insider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of Stock

Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total transaction of $1,470,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aileron Therapeutics Inc (NASDAQ ALRN) traded up $0.06 during trading hours on Thursday, hitting $9.71. 17,512 shares of the company’s stock traded hands, compared to its average volume of 33,876. Aileron Therapeutics Inc has a 12-month low of $8.77 and a 12-month high of $15.48. The firm has a market capitalization of $142.88 and a P/E ratio of -6.94.

Several large investors have recently added to or reduced their stakes in the business. Nexthera Capital LP acquired a new position in shares of Aileron Therapeutics in the second quarter valued at $1,272,000. Goldman Sachs Group Inc. acquired a new position in shares of Aileron Therapeutics in the second quarter valued at $418,000. Laurion Capital Management LP acquired a new position in shares of Aileron Therapeutics in the second quarter valued at $335,000. Neuberger Berman Group LLC acquired a new position in shares of Aileron Therapeutics in the second quarter valued at $279,000. Finally, Citadel Advisors LLC acquired a new position in shares of Aileron Therapeutics in the second quarter valued at $141,000. Hedge funds and other institutional investors own 7.64% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $19.33.

COPYRIGHT VIOLATION WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://transcriptdaily.com/2018/01/11/insider-selling-aileron-therapeutics-inc-alrn-major-shareholder-sells-150000-shares-of-stock.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply